Vigil Neuroscience Inc. (VIGL)
Market Closed
17 Apr, 20:00
NASDAQ (NGS) NASDAQ (NGS) Primary $
1. 71
+0.2
+13.25%
$
104.11M Market Cap
- P/E Ratio
0% Div Yield
76,800 Volume
-2.17 Eps
$ 1.51
Previous Close Day Range
1.5 1.75
Year Range
1.31 6.06
Summary
VIGL closed Thursday higher at $1.71, an increase of 13.25% from Wednesday's close, completing a monthly decrease of -2.84% or $0.05. Over the past 12 months, VIGL stock gained 0.59%.
VIGL is not paying dividends to its shareholders.
The last earnings report, released on Mar 13, 2025, missed the consensus estimates by -0.1%. On average, the company has fell short of earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track VIGL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
VIGL Chart
Vigil Neuroscience Inc. Dividends
VIGL is not paying dividends to its shareholders.
Vigil Neuroscience Inc. Earnings
| 13 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 26 Mar 2024 Date | | - Cons. EPS | - EPS |
VIGL is not paying dividends to its shareholders.
| 13 Mar 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 13 Aug 2024 Date | | - Cons. EPS | - EPS |
| 9 May 2024 Date | | - Cons. EPS | - EPS |
| 26 Mar 2024 Date | | - Cons. EPS | - EPS |
Vigil Neuroscience Inc. (VIGL) FAQ
What is the stock price today?
The current price is $1.71.
On which exchange is it traded?
Vigil Neuroscience Inc. is listed on NASDAQ (NGS).
What is its stock symbol?
The ticker symbol is VIGL.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 104.11M.
Has Vigil Neuroscience Inc. ever had a stock split?
No, there has never been a stock split.
Vigil Neuroscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. CEO | NASDAQ (NGS) Exchange | US92673K1088 ISIN |
| US Country | 69 Employees | - Last Dividend | - Last Split | 7 Jan 2022 IPO Date |
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
Contact Information
Address: 100 Forge Road, Watertown, MA, United States, 02472
Phone: 857 254 4445
Website: https://www.vigilneuro.com
2025 © Marketlog. All Rights Reserved.
